{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:54:48Z","timestamp":1789750488510,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,27]]},"DOI":"10.7759\/cureus.79740","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T11:12:26Z","timestamp":1740654746000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case of Advanced Non-Small Cell Lung Cancer With Hepatocellular Carcinoma-Like Features Responding to a Combination of Durvalumab, Tremelimumab, Carboplatin, and Nab-Paclitaxel"],"prefix":"10.7759","author":[{"given":"Hiroyuki","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Sasada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Kaburaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1515\/med-2021-0215","article-title":"Hepatoid adenocarcinoma of the lung: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database","volume":"16","author":"Lei L","year":"2021","unstructured":"Lei L, Yang L, Xu YY, Chen HF, Zhan P, Wang WX, Xu CW. Hepatoid adenocarcinoma of the lung: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database. Open Med (Wars). 2021, 16:169-74. 10.1515\/med-2021-0215","journal-title":"Open Med (Wars)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100130","article-title":"Hepatoid adenocarcinoma of the lung responsive to frontline combination chemotherapy with immunotherapy: case report","volume":"2","author":"Lagos GG","year":"2021","unstructured":"Lagos GG, Feldman JL, Saqi A, Shu CA. Hepatoid adenocarcinoma of the lung responsive to frontline combination chemotherapy with immunotherapy: case report. JTO Clin Res Rep. 2021, 2:100130. 10.1016\/j.jtocrr.2020.100130","journal-title":"JTO Clin Res Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S248226","article-title":"Anti-PD-1 therapy achieved disease control after multiline chemotherapy in unresectable KRAS-positive hepatoid lung adenocarcinoma: a case report and literature review","volume":"13","author":"Chen L","year":"2020","unstructured":"Chen L, Han X, Gao Y, et al.. Anti-PD-1 therapy achieved disease control after multiline chemotherapy in unresectable KRAS-positive hepatoid lung adenocarcinoma: a case report and literature review. Onco Targets Ther. 2020, 13:4359-64. 10.2147\/OTT.S248226","journal-title":"Onco Targets Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/BF01600112","article-title":"Hepatoid adenocarcinoma: a distinctive histological subtype of alpha-fetoprotein-producing lung carcinoma","volume":"417","author":"Ishikura H","year":"1990","unstructured":"Ishikura H, Kanda M, Ito M, Nosaka K, Mizuno K. Hepatoid adenocarcinoma: a distinctive histological subtype of alpha-fetoprotein-producing lung carcinoma. Virchows Arch A Pathol Anat Histopathol. 1990, 417:73-80. 10.1007\/BF01600112","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1309\/KC09-YTF2-M4DL-UYQ6","article-title":"Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples","volume":"122","author":"Lugli A","year":"2004","unstructured":"Lugli A, Tornillo L, Mirlacher M, Bundi M, Sauter G, Terracciano LM. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol. 2004, 122:721-7. 10.1309\/KC09-YTF2-M4DL-UYQ6","journal-title":"Am J Clin Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000052103.13730.20","article-title":"Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections","volume":"16","author":"Fan Z","year":"2003","unstructured":"Fan Z, van de Rijn M, Montgomery K, Rouse RV. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003, 16:137-44. 10.1097\/01.MP.0000052103.13730.20","journal-title":"Mod Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.02.003","article-title":"Combination of hepatocellular markers is useful for prognostication in gastric hepatoid adenocarcinoma","volume":"45","author":"Osada M","year":"2014","unstructured":"Osada M, Aishima S, Hirahashi M, et al.. Combination of hepatocellular markers is useful for prognostication in gastric hepatoid adenocarcinoma. Hum Pathol. 2014, 45:1243-50. 10.1016\/j.humpath.2014.02.003","journal-title":"Hum Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1947601911411084","article-title":"Ras in cancer and developmental diseases","volume":"2","author":"Fern\u00e1ndez-Medarde A","year":"2011","unstructured":"Fern\u00e1ndez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011, 2:344-58. 10.1177\/1947601911411084","journal-title":"Genes Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.12.019","article-title":"Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: results from LC-SCRUM-Asia study","volume":"176","author":"Tamiya Y","year":"2023","unstructured":"Tamiya Y, Matsumoto S, Zenke Y, et al.. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: results from LC-SCRUM-Asia study. Lung Cancer. 2023, 176:103-11. 10.1016\/j.lungcan.2022.12.019","journal-title":"Lung Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850815)56:4<840::aid-cncr2820560423>3.0.co;2-e","article-title":"An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report","volume":"56","author":"Ishikura H","year":"1985","unstructured":"Ishikura H, Fukasawa Y, Ogasawara K, Natori T, Tsukada Y, Aizawa M. An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report. Cancer. 1985, 56:840-8. 10.1002\/1097-0142(19850815)56:4&lt;840::aid-cncr2820560423&gt;3.0.co;2-e","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.170","article-title":"Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature","volume":"27","author":"Haninger DM","year":"2014","unstructured":"Haninger DM, Kloecker GH, Bousamra Ii M, Nowacki MR, Slone SP. Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature. Mod Pathol. 2014, 27:535-42. 10.1038\/modpathol.2013.170","journal-title":"Mod Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2019.06.023","article-title":"Pulmonary hepatoid adenocarcinoma","volume":"158","author":"Ayub A","year":"2019","unstructured":"Ayub A, Nunez Lopez O, Booth A, Okereke I. Pulmonary hepatoid adenocarcinoma. J Thorac Cardiovasc Surg. 2019, 158:e139-40. 10.1016\/j.jtcvs.2019.06.023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0054","article-title":"A novel approach using sorafenib in alpha fetoprotein-producing hepatoid adenocarcinoma of the lung","volume":"13","author":"Gavrancic T","year":"2015","unstructured":"Gavrancic T, Park YH. A novel approach using sorafenib in alpha fetoprotein-producing hepatoid adenocarcinoma of the lung. J Natl Compr Canc Netw. 2015, 13:387-91; quiz 391. 10.6004\/jnccn.2015.0054","journal-title":"J Natl Compr Canc Netw"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.03.004","article-title":"A mismatch repair-deficient hepatoid adenocarcinoma of the lung responding to anti-PD-L1 durvalumab therapy despite no PD-L1 expression","volume":"13","author":"Basse V","year":"2018","unstructured":"Basse V, Schick U, Gu\u00e9guen P, et al.. A mismatch repair-deficient hepatoid adenocarcinoma of the lung responding to anti-PD-L1 durvalumab therapy despite no PD-L1 expression. J Thorac Oncol. 2018, 13:e120-2. 10.1016\/j.jtho.2018.03.004","journal-title":"J Thorac Oncol"},{"key":"ref15","unstructured":"Clinical Practice Guidelines for Hepatocellular Carcinoma 2021. (2023). Accessed. June 16, 2024: https:\/\/www.jsh.or.jp\/lib\/files\/medical\/guidelines\/jsh_guidlines\/medical\/guideline_jp_2021_cq39_v4.pdf."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000511763","article-title":"Alpha-fetoprotein-producing lung hepatoid adenocarcinoma with brain metastasis treated with S-1","volume":"13","author":"Muroyama Y","year":"2020","unstructured":"Muroyama Y, Tamiya H, Tanaka G, et al.. Alpha-fetoprotein-producing lung hepatoid adenocarcinoma with brain metastasis treated with S-1. Case Rep Oncol. 2020, 13:1552-9. 10.1159\/000511763","journal-title":"Case Rep Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/265310-a-case-of-advanced-non-small-cell-lung-cancer-with-hepatocellular-carcinoma-like-features-responding-to-a-combination-of-durvalumab-tremelimumab-carboplatin-and-nab-paclitaxel","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T11:12:29Z","timestamp":1740654749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/265310-a-case-of-advanced-non-small-cell-lung-cancer-with-hepatocellular-carcinoma-like-features-responding-to-a-combination-of-durvalumab-tremelimumab-carboplatin-and-nab-paclitaxel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.79740","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}